- Home
- HSDT vs YARW Comparison
HSDT vs YARW Comparison
Compare HSDT & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSDT | YARW |
|---|---|---|
| Founded | N/A | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.6M | 154.5M |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | HSDT | YARW |
|---|---|---|
| Price | $2.25 | $19.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $3.50 | ★ $57.00 |
| AVG Volume (30 Days) | ★ 568.6K | 95.5K |
| Earning Date | 11-17-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.27 | 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,017,000.00 | N/A |
| Revenue This Year | $103.59 | N/A |
| Revenue Next Year | $13.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1057.12 | N/A |
| 52 Week Low | $1.19 | $18.05 |
| 52 Week High | $7.20 | $44.28 |
Technical Indicators
Market Signals| Indicator | HSDT | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 43.15 | 39.65 |
| Support Level | $1.94 | $18.24 |
| Resistance Level | $2.40 | $32.89 |
| Average True Range (ATR) | 0.19 | 1.97 |
| MACD | -0.07 | 0.26 |
| Stochastic Oscillator | 12.66 | 32.07 |
Price Performance
Historical ComparisonAbout HSDT Helius Medical Technologies Inc. (DE)
Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities.
About YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.